Financial Analysis: Vaxcyte (NASDAQ:PCVX) vs. Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Vaxcyte (NASDAQ:PCVX – Get Free Report) and Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Institutional & Insider Ownership

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by company insiders. Comparatively, 5.5% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Vaxcyte and Brainstorm Cell Therapeutics’ revenue, earnings per share and valuation.

Vaxcyte is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Vaxcyte and Brainstorm Cell Therapeutics, as provided by MarketBeat.com.

Vaxcyte presently has a consensus target price of $78.50, indicating a potential upside of 6.18%. Brainstorm Cell Therapeutics has a consensus target price of $2.00, indicating a potential upside of 596.38%. Given Brainstorm Cell Therapeutics’ higher possible upside, analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Vaxcyte.

Profitability

This table compares Vaxcyte and Brainstorm Cell Therapeutics’ net margins, return on equity and return on assets.

Risk & Volatility

Vaxcyte has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.

Summary

Brainstorm Cell Therapeutics beats Vaxcyte on 6 of the 10 factors compared between the two stocks.

About Vaxcyte

(Get Free Report)

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

About Brainstorm Cell Therapeutics

(Get Free Report)

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer’s disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Receive News & Ratings for Vaxcyte Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Vaxcyte and related companies with MarketBeat.com’s FREE daily email newsletter.